Spots Global Cancer Trial Database for antibodies, monoclonal
Every month we try and update this database with for antibodies, monoclonal cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma | NCT02340975 | Gastric or Gast... | MEDI4736 + trem... MEDI4736 + trem... MEDI4736 Tremelimumab MEDI4736+tremel... MEDI4736 + trem... | 18 Years - 99 Years | MedImmune LLC | |
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. | |
| Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib | NCT02056080 | Breast Neoplasm | 18 Years - | MedSIR | ||
| A Safety Study of SGN-CD19A for Leukemia and Lymphoma | NCT01786096 | Burkitt Lymphom... Precursor B-cel... | SGN-CD19A | 1 Year - | Seagen Inc. | |
| A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | NCT02519348 | Hepatocellular ... | Tremelimumab Durvalumab Bevacizumab | 18 Years - 99 Years | MedImmune LLC | |
| A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | NCT01716806 | Hodgkin Disease Peripheral T Ce... | brentuximab ved... bendamustine dacarbazine nivolumab | 18 Years - | Seagen Inc. | |
| A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma | NCT01166490 | Gastric Neoplas... Pancreatic Neop... | ASG-5ME | 18 Years - | Seagen Inc. | |
| A Safety Study of SGN-CD19A for B-Cell Lymphoma | NCT01786135 | Burkitt Lymphom... Lymphoma, Folli... Lymphoma, Large... Lymphoma, Mantl... Precursor B-cel... | SGN-CD19A | 12 Years - | Seagen Inc. | |
| A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma | NCT01166490 | Gastric Neoplas... Pancreatic Neop... | ASG-5ME | 18 Years - | Seagen Inc. | |
| A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | NCT02572167 | Hodgkin Lymphom... | brentuximab ved... nivolumab | 18 Years - | Seagen Inc. | |
| A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) | NCT00502112 | Myelodysplastic... | lintuzumab lenalidomide | 18 Years - | Seagen Inc. | |
| ADC-1013 First-in-Human Study | NCT02379741 | Neoplasms Solid Tumors | ADC-1013 | 18 Years - | Alligator Bioscience AB | |
| A Study of Ramucirumab or Icrucumab in Colorectal Cancer | NCT01111604 | Colon Cancer Rectal Cancer | Ramucirumab Icrucumab mFOLFOX-6 | 18 Years - | Eli Lilly and Company | |
| Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | NCT01026415 | Carcinomas Disease, Hodgki... Lymphoma, Large... Lymphoma, Non-H... Neoplasms | brentuximab ved... rifampin midazolam ketoconazole brentuximab ved... | 18 Years - | Seagen Inc. | |
| A Safety Study of SGN-CD19A for B-Cell Lymphoma | NCT01786135 | Burkitt Lymphom... Lymphoma, Folli... Lymphoma, Large... Lymphoma, Mantl... Precursor B-cel... | SGN-CD19A | 12 Years - | Seagen Inc. | |
| A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before | NCT00870870 | Non-Small Cell ... | Gemcitabine Cisplatin IMC-A12 (cixutu... Cetuximab IMC-A12 (cixutu... Cetuximab Carboplatin | 18 Years - | Eli Lilly and Company | |
| Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL | NCT00655837 | Lymphoma, Large... Lymphoma, Non-H... | SGN-40 rituximab gemcitabine | 18 Years - | Seagen Inc. | |
| A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available | NCT00785941 | Advanced Solid ... | IMC-A12 IMC-A12 IMC-A12 IMC-A12 IMC-A12 | 18 Years - | Eli Lilly and Company | |
| A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) | NCT01100502 | Disease, Hodgki... | brentuximab ved... placebo | 18 Years - | Seagen Inc. | |
| Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy | NCT00801177 | Solid Tumors | IMC-11F8 IMC-11F8 IMC-11F8 IMC-11F8 I.V. IMC-11F8 IMC-11F8 IMC-11F8 IMC-11F8 IMC-11F8 IMC-11F8 IMC-11F8 IMC-11F8 | 18 Years - | Eli Lilly and Company | |
| A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available | NCT00785538 | Advanced Solid ... | IMC-A12 IMC-A12 IMC-A12 IMC-A12 IMC-A12 IMC-A12 | 18 Years - | Eli Lilly and Company | |
| A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma | NCT00848926 | Disease, Hodgki... | brentuximab ved... | 12 Years - | Seagen Inc. | |
| A Safety Study of SGN-CD19A for Leukemia and Lymphoma | NCT01786096 | Burkitt Lymphom... Precursor B-cel... | SGN-CD19A | 1 Year - | Seagen Inc. | |
| Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy | NCT00793975 | Advanced Solid ... | IMC-1121B 1121B 1121B 1121B 1121B 1121B 1121B | 18 Years - | Eli Lilly and Company | |
| A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | NCT02519348 | Hepatocellular ... | Tremelimumab Durvalumab Bevacizumab | 18 Years - 99 Years | MedImmune LLC | |
| A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab | NCT00845039 | Colon Cancer Rectal Cancer | Cetuximab Irinotecan IMC-A12 (cixutu... | 18 Years - | Eli Lilly and Company | |
| Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib | NCT02056080 | Breast Neoplasm | 18 Years - | MedSIR | ||
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | NCT02519348 | Hepatocellular ... | Tremelimumab Durvalumab Bevacizumab | 18 Years - 99 Years | MedImmune LLC | |
| A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma | NCT02340975 | Gastric or Gast... | MEDI4736 + trem... MEDI4736 + trem... MEDI4736 Tremelimumab MEDI4736+tremel... MEDI4736 + trem... | 18 Years - 99 Years | MedImmune LLC | |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT02785900 | Acute Myeloid L... | 33A placebo azacitidine decitabine | 18 Years - | Seagen Inc. | |
| A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma | NCT01421667 | Lymphoma, B-Cel... Lymphoma, Large... Lymphoma, Non-H... Lymphoma, T-Cel... | brentuximab ved... rituximab | 6 Years - | Seagen Inc. | |
| A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before | NCT00870870 | Non-Small Cell ... | Gemcitabine Cisplatin IMC-A12 (cixutu... Cetuximab IMC-A12 (cixutu... Cetuximab Carboplatin | 18 Years - | Eli Lilly and Company | |
| A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab | NCT00845039 | Colon Cancer Rectal Cancer | Cetuximab Irinotecan IMC-A12 (cixutu... | 18 Years - | Eli Lilly and Company | |
| A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | NCT02572167 | Hodgkin Lymphom... | brentuximab ved... nivolumab | 18 Years - | Seagen Inc. | |
| A Study of Ramucirumab or Icrucumab in Colorectal Cancer | NCT01111604 | Colon Cancer Rectal Cancer | Ramucirumab Icrucumab mFOLFOX-6 | 18 Years - | Eli Lilly and Company | |
| Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib | NCT02056080 | Breast Neoplasm | 18 Years - | MedSIR | ||
| A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma | NCT00866047 | Lymphoma, Large... Lymphoma, Non-H... | brentuximab ved... | 12 Years - | Seagen Inc. | |
| Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy | NCT01384253 | Breast Neoplasm... Peritoneal Neop... Ovarian Neoplas... Pancreatic Neop... Stomach Neoplas... | ²¹²Pb-TCMC-Tras... trastuzumab | 19 Years - | Orano Med LLC | |
| SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma | NCT00365274 | Anaplastic Larg... | Cyclophosphamid... Doxorubicin hyd... vincristine sul... prednisone SGN-30 | 18 Years - | National Cancer Institute (NCI) | |
| A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available | NCT00785538 | Advanced Solid ... | IMC-A12 IMC-A12 IMC-A12 IMC-A12 IMC-A12 IMC-A12 | 18 Years - | Eli Lilly and Company | |
| Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | NCT01026415 | Carcinomas Disease, Hodgki... Lymphoma, Large... Lymphoma, Non-H... Neoplasms | brentuximab ved... rifampin midazolam ketoconazole brentuximab ved... | 18 Years - | Seagen Inc. | |
| A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms | NCT01309789 | Lymphoma, Large... Lymphoma, NK-ce... Lymphoma, T-cel... | brentuximab ved... cyclophosphamid... brentuximab ved... prednisone cyclophosphamid... doxorubicin doxorubicin prednisone vincristine | 18 Years - | Seagen Inc. | |
| A Study of Ramucirumab or Icrucumab in Colorectal Cancer | NCT01111604 | Colon Cancer Rectal Cancer | Ramucirumab Icrucumab mFOLFOX-6 | 18 Years - | Eli Lilly and Company | |
| Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available | NCT00768391 | Solid Tumors | IMC-3G3 | 18 Years - | Eli Lilly and Company | |
| Cardiac Safety Study of Brentuximab Vedotin (SGN-35) | NCT01026233 | Disease, Hodgki... Lymphoma, Large... Lymphoma, Non-H... | brentuximab ved... | 18 Years - | Seagen Inc. | |
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. | |
| A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma | NCT01950364 | Hodgkin Lymphom... Anaplastic Larg... | brentuximab ved... Brentuximab ved... | 18 Years - 75 Years | Millennium Pharmaceuticals, Inc. | |
| Study of IMC-11F8 in Participants With Colorectal Cancer | NCT00835185 | Metastatic Colo... | IMC-11F8 (necit... Oxaliplatin Folinic acid (F... 5-FU | 18 Years - | Eli Lilly and Company | |
| ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas | NCT01777152 | Anaplastic Larg... Non-Hodgkin Lym... T-Cell Lymphoma | brentuximab ved... doxorubicin prednisone vincristine cyclophosphamid... | 18 Years - | Seagen Inc. | |
| A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma | NCT01990534 | Hodgkin Lymphom... | Brentuximab Ved... | 18 Years - | Takeda | |
| Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma | NCT01874054 | Hodgkin Disease | brentuximab ved... bendamustine | 18 Years - | Seagen Inc. | |
| Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer | NCT00031187 | Prostatic Neopl... | SGN-15 (cBR96-d... Taxotere (docet... | 18 Years - | Seagen Inc. | |
| A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms | NCT01309789 | Lymphoma, Large... Lymphoma, NK-ce... Lymphoma, T-cel... | brentuximab ved... cyclophosphamid... brentuximab ved... prednisone cyclophosphamid... doxorubicin doxorubicin prednisone vincristine | 18 Years - | Seagen Inc. | |
| Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy | NCT00793975 | Advanced Solid ... | IMC-1121B 1121B 1121B 1121B 1121B 1121B 1121B | 18 Years - | Eli Lilly and Company | |
| Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma | NCT00525447 | Multiple Myelom... | SGN-40 lenalidomide dexamethasone | 18 Years - | Seagen Inc. | |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| Study of IMC-EB10 in Participant With Leukemia | NCT00887926 | Myeloid Leukemi... | IMC-EB10 | 18 Years - | Eli Lilly and Company | |
| Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available | NCT00768391 | Solid Tumors | IMC-3G3 | 18 Years - | Eli Lilly and Company | |
| Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) | NCT01925612 | Lymphoma, B-cel... Lymphoma, Large... | brentuximab ved... brentuximab ved... rituximab vincristine cyclophosphamid... prednisone doxorubicin | 18 Years - | Seagen Inc. | |
| Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes | NCT01017731 | Cancer Solid Tumor | IMC-1121B Moxifloxacin Diphenhydramine | 18 Years - | Eli Lilly and Company | |
| A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma | NCT01421667 | Lymphoma, B-Cel... Lymphoma, Large... Lymphoma, Non-H... Lymphoma, T-Cel... | brentuximab ved... rituximab | 6 Years - | Seagen Inc. | |
| Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy | NCT00793975 | Advanced Solid ... | IMC-1121B 1121B 1121B 1121B 1121B 1121B 1121B | 18 Years - | Eli Lilly and Company | |
| A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma | NCT01015911 | Carcinoma, Rena... Lymphoma, Non-H... | SGN-75 | 18 Years - | Seagen Inc. | |
| Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer | NCT00031187 | Prostatic Neopl... | SGN-15 (cBR96-d... Taxotere (docet... | 18 Years - | Seagen Inc. | |
| Study of IMC-EB10 in Participant With Leukemia | NCT00887926 | Myeloid Leukemi... | IMC-EB10 | 18 Years - | Eli Lilly and Company | |
| A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study | NCT00947856 | Disease, Hodgki... Lymphoma, Large... Lymphoma, Non-H... | brentuximab ved... | 6 Years - | Seagen Inc. | |
| A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | NCT01716806 | Hodgkin Disease Peripheral T Ce... | brentuximab ved... bendamustine dacarbazine nivolumab | 18 Years - | Seagen Inc. | |
| Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer | NCT03951415 | Endometrial Neo... Uterine Neoplas... Endometrium Can... | PARP inhibitor ... | 18 Years - | Leiden University Medical Center | |
| A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies | NCT00649584 | Disease, Hodgki... Lymphoma, Large... Lymphoma, Non-H... | SGN-35 gemcitabine | 12 Years - | Seagen Inc. | |
| Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies | NCT00430846 | Lymphoma, Non-H... Disease, Hodgki... Lymphoma, Large... | SGN-35 | 18 Years - | Seagen Inc. | |
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. | |
| A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors | NCT03369223 | Advanced Cancer | BMS-986249 Nivolumab Ipilimumab | 18 Years - | Bristol-Myers Squibb |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
